We are live on ! Find out more
ELEV

Elevation Oncology
ELEV

Delisted

ELEV was delisted on the 22nd of July, 2025.

Back to rankings

36 hedge funds and large institutions have $217M invested in Elevation Oncology in 2021 Q2 according to their latest regulatory filings, with 36 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

70.96% more ownership

Funds ownership: 0% → 70.96% (+71%)

Holders
36
Holders Change
+36
Holders Change %
–
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.03%
New
36
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACM
Aisling Capital Management
New York
+$35M
2
VP
venBio Partners
California
+$32.2M
3
DCM
Driehaus Capital Management
Illinois
+$24.7M
4
CAM
Cormorant Asset Management
Massachusetts
+$24.5M
5
BI
BVF Inc
California
+$19.7M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
Aisling Capital Management
New York
$38.5M +$35M +2,834,910 New
VP
2
venBio Partners
California
$35.4M +$32.2M +2,608,167 New
DCM
3
Driehaus Capital Management
Illinois
$26.5M +$24.7M +1,999,514 New
CAM
4
Cormorant Asset Management
Massachusetts
$25.6M +$24.5M +1,983,165 New
BI
5
BVF Inc
California
$21.6M +$19.7M +1,590,291 New
BC
6
Boxer Capital
California
$18.2M +$16.6M +1,341,530 New
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$13.6M +$12.8M +1,031,688 New
SB
8
Samsara BioCapital
California
$12.7M +$11.5M +932,239 New
VC
9
Vivo Capital
California
$6.74M +$6.14M +496,843 New
MIM
10
Monashee Investment Management
Massachusetts
$1.9M +$1.73M +140,000 New
Alyeska Investment Group
11
Alyeska Investment Group
Illinois
$1.7M +$1.54M +125,000 New
PAMP
12
Polar Asset Management Partners
Ontario, Canada
$1.7M +$1.54M +125,000 New
Millennium Management
13
Millennium Management
New York
$1.67M +$1.52M +123,062 New
WP
14
Woodline Partners
California
$1.53M +$1.39M +112,431 New
GTC
15
Ghost Tree Capital
New York
$1.36M +$1.24M +100,000 New
HM
16
HealthCor Management
New York
$1.36M +$1.24M +100,000 New
Hudson Bay Capital Management
17
Hudson Bay Capital Management
Connecticut
$1.09M +$989K +80,000 New
Goldman Sachs
18
Goldman Sachs
New York
$848K +$773K +62,500 New
CCM
19
CAAS Capital Management
New York
$814K +$742K +60,000 New
Vanguard Group
20
Vanguard Group
Pennsylvania
$814K +$742K +60,000 New
Point72 Asset Management
21
Point72 Asset Management
Connecticut
$679K +$618K +50,000 New
CC
22
Caxton Corporation
New Jersey
$537K +$489K +39,586 New
PCM
23
Pinz Capital Management
New York
$494K +$450K +36,400 New
LP
24
LMR Partners
United Kingdom
$425K +$387K +31,300 New
SFM
25
Sphera Funds Management
Israel
$407K +$371K +30,000 New
1
2

ELEV Hedge Fund Activity: Q2 2021 in Review

36 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q2 2021, worth a combined $217M.

Buyers outnumbered sellers: 36 funds opened new ELEV positions and 0 closed out — a net gain of 36 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Aisling Capital Management, opening a new position worth an estimated $35M.

  • 36 institutional investors held Elevation Oncology (ELEV) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $217M of Elevation Oncology stock for Q2 2021.
  • 36 funds opened new Elevation Oncology positions in Q2 2021 and 0 closed out, a net change of +36 holders.
  • The largest Elevation Oncology buyer in Q2 2021 was Aisling Capital Management, an estimated $35M added.

Based on aggregated 13F filings for Q2 2021.